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Abstract Mouse perlecan domain II (325 residues), consisting 
of four cysteine-rich LA modules, one IG module and a link 
region, was obtained in purified form from a stably transfected 
mammalian cell clone. Rotary shadowing electron microscopy 
demonstrated a globular domain connected to a short rod-like 
segment of variable length. This suggested that tandem arrays of 
LA modules form rod-like elements. Folding into a native 
structure was indicated by the sharing of immunological epitopes 
with tissue perlecan, a CD spectrum demonstrating 37% [~ 
structure and a limited susceptibility to proteolysis. The domain 
also showed N-glycosylation of a single acceptor site and 7-8 
O-linked oligosaccharides. The latter were located mainly in the 
link region within proline-rich sequences. 
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also predicted to contain a novel protein module (SEA) 
with a mixed all 3 conformation [17] which was in fact shown 
by CD spectroscopy (Costell and Timpl, in preparation). 
In the present study we have examined the structure of 
perlecan domain II which is the connecting segment between 
domains I and III. Domain II was predicted to contain four 
LDL receptor class A (LA) modules [7] of about 40 residues 
including six cysteines, a single immunoglobulin-like (IG) 
module (100 residues) and a link region of 44 residues [8- 
10]. The analysis of the recombinant domain II demonstrated 
that it represents an autonomously folding unit within the 
perlecan structure and revealed unique spatial features of 
this protein segment as well as its glycoconjugation. 
2. Materials and methods 
1. Introduction 
Perlecan has been identified as the major heparan sulfate 
proteoglycan of basement membranes and some other extra- 
cellular structures and has been shown to bind to integrin cell 
receptors, laminin, collagen IV, nidogen, fibronectin and sev- 
eral more ligands [1-3]. It has also been implicated in the 
control of renal filtration through basement membranes and 
the storage or presentation of cytokines such as basic fibro- 
blast growth factor [4,5]. Mouse perlecan obtained from a 
tumor consists of an elongated 480 kDa core protein and 
three glycosaminoglycan chains [6]. Sequence analysis of 
cDNA clones demonstrated the presence of seven different 
extracellular protein modules (see [7] for their definition) 
which are arranged in different clusters referred to as domains 
I -V [8-10]. The shape and conformation of these domains as 
well as their specific binding properties are so far largely un- 
known. 
Since perlecan is difficult to purify from tissue extracts and 
very likely obtained in partially denatured form [6,11], the 
recombinant production of its individual domains was re- 
cently chosen as an alternative approach for structural and 
functional studies. Such studies were performed for the central 
domain III of perlecan which consists of alternating arrays of 
laminin domain IV type (L4) and laminin epidermal growth 
factor-like (LE) modules [12 14]. Electron microscopical data 
indicated the presence of globular (L4) domains connected by 
short rods (LE modules) consistent with X-ray structure data 
for consecutive laminin LE modules which form rods [15]. 
The N-terminal perlecan domain I was shown to contain 
the glycosaminoglycan attachment sites [16]. Domain I was 
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2.1. Vector construction and recombinant production 
Mouse perlecan cDNA clone 54 [8] was used as a template to 
amplify the sequence ncoding domain II (amino acid residues 195 
519) by polymerase chain reaction (PCR) with Taq DNA polymerase 
(Boehringer Mannheim) following the manufacturer's instructions. 
The primer for the 5' end was GATCGCTAGCGTTCCCAA- 
GAGTCTGCAC and that for the 3' end was GATCCTCGAGTCA- 
CAGGCAGGAGGCACTGTCTT which introduced, in addition to 
the coding sequences, a stop codon and single NheI and Xhol restric- 
tion sites in order to allow in-frame insertion of the cDNA distal to 
the BM-40 signal peptide sequence [18]. Several clones, however, 
showed a C to T mutation at nucleotide position 1976, which would 
change an Arg to a stop codon, and were repaired by PCR with the 
5' primer CACTGCATCCCCCGAGACTACCTC and 3' primer 
GAGGTAGTCTCGGGGGATGCAGTG following an established 
protocol [19]. The corrected construct was then cloned into the eu- 
karyotic expression vector pRc/CMV (Invitrogen) and its structure 
verified by DNA sequencing using Sequenase version 2.0 (US Bio- 
chemical Co.). Human embryonic kidney 293 cells were cotransfected 
with the expression vector and plasmid pSV2pac. Stable transfectants 
were selected with puromycin and serum-free culture medium from 
regular culture plates was collected as previously described [20]. 
2.2. Purification of prote&s 
Recombinant domain II was isolated from 1 liter conditioned se- 
rum-free medium on a DEAE cellulose column (2×30 cm) equili- 
brated in 2 M urea, 0.05 M Tris-HCl pH 8.6 containing protease 
inhibitors [21]. The protein eluted in a major peak at 0.15-0.2 M 
NaC1 in the linear NaCI gradient (0~0.4 M NaCI, 500 ml). This 
peak was dialyzed against 0.2 M NH4HCO3 and lyophilized to yield 
almost homogeneous domain II. Perlecan was purified from a tumor 
basement membrane as described [6] and recombinant perlecan frag- 
ments [13,14] from 293 cell culture medium. Proteins were reduced 
with 0.02 M dithiothreitol in 6 M guanidine and alkylated with iodo- 
acetamide or vinylpyridine following standard protocols. 
2.3. Proteolysis and sequence analysis 
Digestion of domain II in 0.2 M NH4HCO3 with endoproteinases 
GIu-C (Boehringer Mannheim) and Lys-C (Wako Chemicals, Neuss), 
trypsin (Worthington) or plasmin (Kabi AB) was carried out at en- 
zyme-substrate ratios of 1:100 at 37°C for different ime periods. 
Major fragments were separated by SDS gel electrophoresis, blotted 
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onto Immobilon PSQ membranes (Millipore) and used for sequenc- 
ing. Other aliquots of some digests were reduced and alkylated and 
separated by reverse-phase chromatography [21] and used to identify 
glycosylated peptides by hexosamine analysis. Edman degradation of
fragments (50-200 pmol) was performed on 473A, 470A and Procise 
sequencers (Applied Biosystems) following the manufacturer's in truc- 
tions. 
2.4. Analytical and miscellaneous methods 
Samples were hydrolyzed with 6 M or 3 M HC1 (16 h, II0°C) to 
determine amino acid and hexosamine compositions, respectively, on
a LC 3000 analyzer (Biotronik). SDS gel electrophoresis in 20% poly- 
acrylamide gels followed standard protocols. Circular dichroic spectra 
were recorded with a Mark IV automatic spectropolarimeter (ISA, 
Jobin Yvon) at 20°C in quartz cells. Radioimmunoassays [22] and 
rotary shadowing electron microscopy [23] followed established pro- 
tocols. 
3. Results 
The modular structure of perlecan domain II [8] is mainly 
characterized by four LA modules each with about 40 residues 
including six invariant cysteines as initially shown for LDL 
receptor [24]. These modules occur in a tandem array, except 
modules LA1 and LA2 which are separated by a 44 residue 
link region, followed by a single immunoglobulin-like module 
IG1 and an extra disulfide-bonded loop (E) at the C-terminus 
(Fig. la). An expression vector for domain II of mouse perle- 
can (position 195-519) with a foreign signal peptide was pre- 
pared and several stably transfected kidney cell clones were 
obtained which produced and secreted recombinant fragment 
II. Purification to > 95% homogeneity could be achieved by a 
single chromatographic step on DEAE cellulose with high 
yields (15 20 mg fragment II per liter culture medium). Ed- 
man degradation of fragment II demonstrated the expected 
N-terminal sequence APLAFPRV with APLA being derived 
from the signal peptide region [8,18]. SDS gel electrophoresis 
showed a single band of about 45 kDa for non-reduced frag- 
ment II (Fig. 2), in agreement with a molecular mass of 36 
kDa calculated from the sequence assuming some additional 
glycosylation. Glycosylation of the recombinant protein was 
confirmed by hexosamine analysis howing 7.3 + 1.2 residues 
of glucosamine and 7.6 + 1.0 residues of galactosamine. This 
indicates full occupation of the single N-glycosylation site in 
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the LA3 module (Fig. la) and about 70-glycosylation sites in 
fragment II. 
Rotary shadowing electron microscopy of recombinant 
fragment II demonstrated a rather uniform set of particles 
with an average length of 18+4 nm (Fig. 3). Typical for 
this structure was a small globular domain connected to a 
thin stalk of 10-15 nm length. A distinct folding of the frag- 
ment was also shown by its CD spectrum which had a distinct 
minimum at 198 nm (Fig. 4). This indicated a 37% content of 
structure with only low or insignificant amounts of cz helix 
[25]. These observations also suggested an extensive and prob- 
ably correct disulfide bonding among the 28 cysteines present 
in fragment II. Disulfide bonding was indicated by a distinct 
decrease in electrophoretic mobility observed after reduction 
of fragment II (Fig. 2). Further evidence was obtained by 
radioimmuno-inhibition assay used for epitope analysis of a 
polyclonal rabbit antiserum against fragment II (Fig. 5). This 
demonstrated equally high inhibitory capacities for non-re- 
duced fragment II and tissue-derived perlecan but a more 
than 10000-fold loss of reduced and alkylated fragment II. 
Furthermore, other recombinant perlecan fragments uch as 
III-3 [13] showed no inhibition demonstrating the presence of 
unique conformational antibody binding epitopes on fragment 
II. 
Proteolysis and sequence analysis were performed to exam- 
ine disulfide bonding and the presence of flexible hinge regions 
and oligosaccharide substitutions. Digestions with trypsin, en- 
doproteinases Lys-C or Glu-C produced similar but not iden- 
tical cleavage patterns of fragment II including components of
about 40, 22 and 4/5 kDa when analyzed by electrophoresis 
under non-reducing conditions (Fig. 2). No reduction in mo- 
bility was, however, observed after a 24 h treatment with 
plasmin. Yet, all four digests howed a more distinct increase 
in mobility, including that with plasmin (components of 20-43 
kDa), of individual components when examined under reduc- 
ing conditions (data not shown), indicating that cleavage 
occurred in intermodular segments as well as within disul- 
fide-bonded loops of individual modules. This could be con- 
firmed by sequence analysis of the major fragments already 
released without reduction (Table 1, Fig. lb). The data for the 
40 kDa band demonstrated a release after cleavage within the 
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Fig. 1. Module arrangement of perlecan domain II and identification of major protease sensitive bonds and oligosaccharide attachment sites. 
a: Modules include four LDL receptor class A repeats (LA), one immunoglobulin superfamily repeat (IG), an extra disulfide-bonded loop (E) 
and a few link regions (straight lines). Numbers underneath indicate their approximate borders by sequence positions [8]. NCS denotes the 
single N-glycosylation site. b: Approximate positions of major cleavage sites by trypsin (T), endoproteinase Glu-C (G) and endoproteinase 
Lys-C (L) identified by the position numer of the newly generated N-terminus (see Table 1). c: Predicted eDNA sequence of the major link re- 
gion [8] with the portion confirmed by Edman degradation being underlined. A gap in the sequence or a strongly reduced yield of the respec- 
tive PTH-amino acid was interpreted to indicate full (O) or partial (©) O-glycosylation, respectively. 
M. Costell et aL/FEBS Letters 396 (1996) 127-131 129 
+ - L G T 
67-  
45-  
31-  
22-  
14-  
6,5- 
: :: 42 43 
40 40 
23 
22 i 22 
5 5 
4 ...... 4 
Fig. 2. Electrophoretic analysis of recombinant perlecan domain II 
and of several proteolytic digests. The left two lanes show intact 
fragment II after (+) and prior ( - )  to reduction. Numbers at the 
left margin denote the position of calibrating proteins in kDa. Pro- 
teolytic digests of fragment II were obtained with endoproteinases 
Lys-C (L) and Glu-C (G) each for 4 h and with trypsin (T) for 1 h 
and separated under non-reducing conditions• Major fragments ub- 
jected to sequencing are identified by their molecular masses (in 
kDa). 
link between LA1 and LA2 modules (G40,42, Table l) or 
demonstrated the N-terminus (L40, T43, Table 1) indicating 
here shortening at the C-terminus. All fragments contained in 
addition internal loop cleavage sites within the LA1, LA3, 
LA4 and/or the IG1 module. The 22 kDa components were 
apparently released by a cleavage between modules LA3 and 
LA4 with additional cleavages within the LA4 or IG1 module• 
The 4/5 kDa double bands corresponded to either the LA1 or 
the extra loop (E) modules or portions of the IG1 module. 
Initial sequence analysis of fragments starting in the pre- 
dicted large link region between the LAI  and LA2 modules 
(L26,32; G40,42; see Table 1) showed in addition the inter- 
esting feature of a gap in the sequence at positions that should 
be occupied by Ser or Thr [8] indicating the possible modifi- 
Fig. 3. Electron micrograph of rotary shadowed fragment II. Note 
the frequent appearance of a globular structure connected to a short 
stalk. 
cation by O-glycosylation. Reduced and alkylated fragments 
were therefore further purified by reversed phase chromatog- 
raphy and revealed only two peaks which contained more 
than 80% of the total galactosamine recovered (data not 
shown). These fragments allowed a substantial sequence ana- 
lysis of the link region demonstrating full substitution for 
Ser 243, Ser 252, Thr 262 and Thr 263 and partial substitution 
(> 50%) for Thr 245 and Thr 269 (Fig. lc) estimated from the 
yields of derivatized amino acids. 
4.  D iscuss ion  
The data reported in this study demonstrate by recombi- 
nant production that the predicted omain II of the basement 
membrane proteoglycan perlecan represents an autonomous 
folding unit within its large core protein. This autonomy 
may even exist at the level of individual modules which, how- 
ever, remains to be shown. Folding of recombinant fragment 
II into a native structure was indicated by electron micros- 
copy, by the presence of a distinct secondary structure as 
Table 1 
Amino-terminal sequences of major fragments produced from perlecan domain II by cleavage with endoproteinases Glu-C (G) and Lys-C (L) 
and by trypsin (T) 
Protease, fragment size (kDa) Sequence Cleaved peptide bond and position Localization in modules 
L 40 APLAFPRV - N-terminus 
LWRXD KL,340/341 LA3 
22,23 QPGEVX KL,362/363 border LA3/4 
EADQG KE,469/470 IG 1 
26,32 a APLAFPRV N-terminus 
VXPLPLW KV,250/251 link 
G 40,42 LSXSTPAV EL,240/241 link 
FGXMPP EF,400/401 LA4 
ADQGA EA,471/472 IG1 
4-5 APLAFRV - N-terminus 
LVPQR EL,497/498 border IGI/E 
T 43 VVXTET RV,197/198 front LA1 
DMSDELN RD,226/227 LA 1 
XIPASFH RC,380/381 LA4 
22 QPGEV KL,362/363 border LA3/4 
X1PAS RC,380/381 LA4 
4-5 GQTVT RG,420/421 IG 1 
EADQG KE,470/471 IG 1 
GMVFG RG,485/486 border IGI/E 
~Minor component by protein staining. 
Components were separated by electrophoresis under non-reducing 
fragments and Fig. 1 for modules. 
conditions prior to sequencing. Compare Fig. 2 for the identification of 
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Fig. 4. Circular dichroism spectrum of recombinant perlecan frag- 
ment II. 
shown by CD spectroscopy and by the complete cross-reac- 
tion with tissue-derived perlecan in quantitative immuno- 
chemical assays. Furthermore an extensive disulfide bonding 
within fragment II was demonstrated by proteolysis and the 
complete loss of immunological epitopes upon reduction and 
alkylation. 
A globular domain and a thin rod represent the topological 
features of fragment II. These two structural elements are also 
typical for the electron microscopical ppearance of the core 
protein of perlecan [6] indicating that domain II could con- 
tribute about 20% of the total length of the core. It is very 
likely that the globular domain corresponds to the IG1 mod- 
ule and accounts for most of the 13 structure, since these are 
typical features of similar modules found in immunoglobulins 
[26]. This suggests that the tandem array of four LA modules 
contributes the rod-like element of fragment II which was so 
far not known before. Such modules obviously must have a 
compact structure due to the three overlapping disulfide 
bridges as shown for a single recombinant LA module of 
LDL receptor [27]. Similar compact structures are known to 
exist in the laminin-type LE modules and EGF-like modules 
which are of comparable size but have a different disulfide 
bond connectivity [15,28]. Also these latter modules have 
been shown to form rod-like structures if they occur in tan- 
dem arrays. Whether tandem arrays of LA modules form rod- 
like structures will require further recombinant analysis of 
perlecan domain lI as well as of other proteins howing simi- 
lar arrangements. The only other protein known so far is the 
LDL receptor which contains a consecutive array of seven LA 
module at its N-terminal region [24]. 
Proteolysis was used as a probe to identify connecting inter- 
modular segments within perlecan domain II. This demon- 
strated cleavage of a 44 residue link region which separates 
the LAI and LA2 modules and is particularly rich in Pro, Thr 
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and Set (Fig. lc). Some shorter protease-sensitive connecting 
segments apparently exists between modules LA3 and LA4 
and possibly between LA4 and IG1. Yet significant cleavage 
was also observed within disulfide-bonded loops of IG1 and 
three LA modules (Fig. lb) which indicates the existence of 
exposed loop structures. These observations are supported by 
a similar trypsin sensitivity of the LA1 module of the LDL 
receptor [27] which shows that this property is a general fea- 
ture of LA modules. The link region between the LA1 and 
LA2 modules of perlecan domain II was also shown to harbor 
six O-glycosylation sites consistent with the presence of 7 8 
galactosamines and particular features of its sequence. This 
indicates a short mucin-like segment in domain II which could 
be responsible for the size variation observed for the rod-like 
segment. It was also of interest hat all except one of the 
substituted Ser and Thr had a Pro in the +3 position which 
fulfils one of the requirements postulated for O-glycosylation 
[29]. 
The LA module region of LDL receptor was previously 
shown to be important for the binding of extracellular ligands. 
A mutational analysis demonstrated that LDL binding 
through ApoB-100 required the consecutive array of five LA 
modules while only the LA5 module was necessary for pro- 
moting VLDL binding through ApoB [30]. Site-directed mu- 
tagenesis further identified a conserved Ile and Asp as crucial 
residues within the binding epitopes. Both residues are invar- 
iant, except for a few conservative substitutions, in the LA 
modules of perlecan [8-10]. Nidogen [1] and fibulin-2 [31] are 
the only extracellular binding proteins of the perlecan core 
protein that have been identified so far. Preliminary evidence 
was obtained that nidogen binds to recombinant fragment II
although less strongly than to perlecan (M. Costell and R. 
Timpl, unpublished). Further studies with the recombinant 
fragment will therefore be necessary to establish whether do- 
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Fig. 5. lmmunochemical analysis of fragment II by radio-immuno- 
inhibition assay. The assay system consisted of 125I-labelled frag- 
ment II and a rabbit antiserum against fragment II. Inhibitors used 
were perlecan (O), perlecan fragment II (©), reduced and alkylated 
fragment II (A) and perlecan fragment III-3 ([]). 
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main II has distinct binding properties or just serves as a 
spacing element within the elongated core protein of perlecan. 
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